Artiva Biotherapeutics, Inc. (ARTV)
| Market Cap | 204.85M +91.0% |
| Revenue (ttm) | n/a |
| Net Income | -90.82M |
| EPS | -3.21 |
| Shares Out | 48.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,966,165 |
| Open | 4.200 |
| Previous Close | 4.230 |
| Day's Range | 4.100 - 4.260 |
| 52-Week Range | 2.960 - 14.530 |
| Beta | 2.68 |
| Analysts | Buy |
| Price Target | 20.75 (+395.23%) |
| Est. Earnings | Nov 16, 2026 |
About ARTV
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/mic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ARTV stock is "Buy." The 12-month stock price target is $20.75, which is an increase of 395.23% from the latest price.
News
Artiva Biotherapeutics downgraded to Hold from Buy at Jefferies
Jefferies last night downgraded Artiva Biotherapeutics (ARTV) to Hold from Buy with a price target of $4, down from $23. The firm cites the discontinuation of AlloNK after longer-term data…
Artiva Biotherapeutics downgraded to Hold from Buy at Jefferies
Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold from Buy with a price target of $4, down from $23.
Why Is Artiva Biotherapeutics Stock (ARTV) Down 31% Today?
Artiva Biotherapeutics stock fell over 30% on Tuesday after the company said it’s considering strategic alternatives, has plans to lay off 94% of employees, and has ended work on AlloNK.
Artiva Biotherapeutics downgraded to Hold at Needham after discontinuing AlloNK
Needham analyst Gil Blum downgraded Artiva Biotherapeutics (ARTV) to Hold from Buy without a price target after the company announced the discontinuation of AlloNK development following two patient de...
Artiva Biotherapeutics downgraded to Hold from Buy at Needham
Needham downgraded Artiva Biotherapeutics (ARTV) to Hold from Buy.
Artiva Biotherapeutics downgraded to Neutral at Wedbush after patient death
Wedbush analyst David Nierengarten downgraded Artiva Biotherapeutics (ARTV) to Neutral from Outperform with a price target of $4, down from $40. A patient death has been attributed to fludarabine toxi...
Artiva Biotherapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Artiva Biotherapeutics (ARTV) to Neutral from Outperform.
Artiva Biotherapeutics downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Artiva Biotherapeutics (ARTV) to Hold from Buy without a price target after the company halted development of its lead candidate, AlloNK, for autoimmune conditions after a Grade…
Artiva Biotherapeutics down 26% after discontining development of AlloNK
Artiva shares are down $1.62, or 26%, to $4.54 in pre-market trading.
Artiva to discontinue AlloNK, reduce workforce by 94% and evaluate alternatives
Artiva Biotherapeutics (ARTV) announced that it will discontinue further development of AlloNK, its non-genetically modified, allogeneic NK cell therapy candidate being evaluated in combination with r...
Artiva Biotherapeutics trading halted, news pending
07:26 EDT Artiva Biotherapeutics (ARTV) trading halted, news pending
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported fin...
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemi...
Artiva updates safety, translational data for AlloNK with rituximab
Artiva Biotherapeutics (ARTV) highlighted updated clinical, safety and translational data for AlloNK in combination with rituximab, presented by Guillermo Valenzuela, M.D., F.A.C.R., medical director ...
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
Artiva Biotherapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
AlloNK combines non-engineered NK cells with rituximab for deep B-cell depletion, with community treatment and no CRS or ICANS reported in more than 100 autoimmune patients. A 150-patient randomized RA trial targets a readout before the end of 2028; May 2026 financing extends runway into 2029.
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren's Disease
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible ce...
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible ce...
Artiva Biotherapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing deep B-cell depletion and strong efficacy in early trials. Phase III is underway with robust funding, rapid community-based enrollment, and plans for broader autoimmune indications.
Artiva Biotherapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A novel NK cell platform is advancing in autoimmune disease, with a pivotal phase III trial in refractory RA targeting deep B-cell depletion and showing promising early efficacy and safety. The competitive landscape is favorable, and expansion into other indications is planned, with key data updates expected by year-end.
Artiva Biotherapeutics provides update on AlloNK data disclosures
Artiva Biotherapeutics (ARTV) provided an update on anticipated data disclosures and development milestones for its lead program, AlloNK, through year-end 2026. Artiva expects to disclose updated clin...
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2...
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible ce...
Artiva Biotherapeutics files $400M mixed securities shelf
17:27 EDT Artiva Biotherapeutics (ARTV) files $400M mixed securities shelf
Artiva Biotherapeutics reports Q2 EPS (63c), consensus (64c)
“The second quarter was transformative for Artiva. The clinical and translational data presented at EULAR reinforced AlloNK’s potential to drive deep B-cell depletion and meaningful clinical responses...